SynthesisFrontiers in pharmacology2022
Research Status and Hotspots of Anticancer Natural Products Based on the Patent Literature and Scientific Articles.
Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Anticancer Potential of Atractylenolides I-III: Efficacy, Mechanisms, Pharmacokinetics, and Safety.Molecules (Basel, Switzerland) · 2026Review
- Alkaloids isolated from Scutellaria Barbata D. Don trigger apoptosis and inhibit migration by modulating the p38-p53 pathway in ovarian cancer.Journal of ovarian research · 2025Article
- The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.BMC neurology · 2025Article
- A Patent Analysis on Nano Drug Delivery Systems.Recent patents on nanotechnology · 2025Review
- Herbal based nanoparticles as a possible and potential treatment of cancer: a review.Exploration of targeted anti-tumor therapy · 2025Review
- Bridging the Gap: Scenario Planning for Science and Technology in Breast Cancer.Medical journal of the Islamic Republic of Iran · 2025Article
- Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure-activity relationship, and prospects for clinical advancement.Pharmacological reports : PR · 2024Review
- Emodin inhibits bladder inflammation and fibrosis in mice with interstitial cystitis by regulating JMJD3.Acta cirurgica brasileira · 2023Article
- Bovine Colostrum Treatment of Specific Cancer Types: Current Evidence and Future Opportunities.Molecules (Basel, Switzerland) · 2022Review
- Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges.Drug delivery · 2022Review
- Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.